Nucryst Doubles On FDA Approval For Prescription Cream

This article is now exclusive for PRO subscribers.

Nucryst Pharmaceuticals Corp. (NCST) shares shot through the roof and then some Friday morning, rising more than 100%, following the company announcement late Thursday afternoon that the U.S. Food & Drug Administration has approved a prescription-only topical antimicrobial cream.

Nucryst, whose patented nanocrystalline silver compound is currently used in Smith & Nephew plc's (NYSE:SNN) Acticoat advanced wound care products, will now begin marketing the new cream that will be used to fight against infections and inflammation.

Nucryst president and CEO Scott Gillis said in a statement that market plans and timing for this product will be determined as part of the commercialization process.

NCST 1-yr chart:
ncst chart